Catalyst Pharmaceuticals Inc (CPRX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $31.49 (+0.03%), Market cap $3.82B, P/E ratio 18.04, 52-week low–high $19.13 ~ $31.23.
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and l
Financial statements, price targets, institutional (13F) holdings and related news for Catalyst Pharmaceuticals Inc are updated in real time on BlackAll Trade.
Catalyst Pharmaceuticals Inc trades at $31.49 (+0.03%). Real-time quotes and charts are available on BlackAll Trade.
Catalyst Pharmaceuticals Inc has a market cap of about $3.82B. Its P/E ratio is 18.04.
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers